1.	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Phase: Phase IV Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TRE1001, NCT01161563
2.	Phase III Randomized Study of Adjuvant Tamoxifen With or Without Ovarian Suppression and/or Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Premenopausal Women With Stage I-IIIA, Unilateral, Invasive Breast Cancer (Summary Last Modified 12/2001) Phase: Phase III Type: Treatment Status: Closed Age: 70 and under Sponsor: Protocol IDs: SCTN-BR9401, EU-94002, UKCCCR-ABC/BR9401, NCT00002580
3.	Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression, and/or Chemotherapy in Women With Stage I, II, and IIIA Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Protocol IDs: NCRI-ABC, CRC-TU-BR3010, SCTN-BR9401/BR9402, YRCO-ABC, EU-94029, UKCCCR-ABC, NCT00002582
4.	Phase III Randomized Study of Adjuvant Tamoxifen with vs without Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer 3 cm or Less in Diameter (Summary Last Modified 03/98) Phase: Phase III Type: Treatment Status: Completed Age: premenopausal Sponsor: NCI Protocol IDs: E-3193, CLB-9494, NCCTG-933252, SWOG-9347, INT-0142, E3193
5.	Phase III Randomized Study of Radiotherapy With or Without Neoadjuvant Flutamide Plus Goserelin or Leuprolide in Patients With Good Prognosis, Locally Confined Adenocarcinoma of the Prostate Phase: Phase III Type: Treatment Status: Completed Age: Any age Sponsor: NCI Protocol IDs: RTOG-9408, NCT00002597, RTOG-94-08
6.	Phase III Randomized Study of Radical Prostatectomy with vs without Neoadjuvant Hormone Therapy Using Leuprolide or Goserelin and Flutamide or Bicalutamide for Stage I/II Prostate Cancer (Summary Last Modified 08/98) Phase: Phase III Type: Treatment Status: Completed Age: 18 to 70 Sponsor: NCI Protocol IDs: SWOG-S9615, SWOG-9615, S9615
7.	Phase III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With or Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the Prostate Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-8892, CLB-E8892, SWOG-E8892, NCT00002881, E8892
8.	Phase III Study of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate (Summary Last Modified 11/98) Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: RTOG-9608, RTOG-96-08
9.	Hormone Therapy in Treating Patients Who Have Stage I or Stage II Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Other Protocol IDs: ID97-077, P30CA016672, MDA-ID-97077, E-97077, NCI-T97-0069, CDR0000066733, T97-0069, NCT00003645
10.	Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 000080, 00-C-0080, NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085, NCT00004635
11.	Phase III Randomized Study of Treosulfan Versus Leuprolide in Patients With Platinum and Paclitaxel-Refractory Ovarian Epithelial Carcinoma (Summary Last Modified 04/2001) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 80 Sponsor: Protocol IDs: AGOSG-OVAR-2.1
12.	Phase III Randomized Comparison of Leuprolide/Flutamide vs Leuprolide Alone in Previously Untreated Patients with Stage D2 Adenocarcinoma of the Prostate Phase: Phase III Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-8494, MAOP-4384, NCCTG-INT-0036, NCOG-4P842J, NPCTG-2200, INT-0036
13.	Phase III Randomized Comparison of Hormonal Therapy with Leuprolide Alone vs Leuprolide/Tamoxifen in Premenopausal Breast Cancer Patients with Metastatic Disease (Summary Last Modified 10/87) Phase: Phase III Type: Treatment Status: Closed Age: premenopausal Sponsor: Protocol IDs: MSHMC-1609, NCI-V87-0248
14.	Phase III Randomized Trial of Surgical or Medical Castration plus Hydrocortisone Followed by Chemotherapy with CTX/ADR/5-FU with vs without Stimulative Hormonal Therapy with Fluoxymesterone in Previously Untreated Patients with Advanced Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 84 Sponsor: Protocol IDs: MSHMC-1642, NCI-V87-0249
15.	Phase III Randomized Comparison of Leuprolide/Anandron vs Leuprolide/Placebo in Patients with Stage D2 Carcinoma of the Prostate Phase: Phase III Type: Treatment Status: Completed Age: 40 to 85 Sponsor: Protocol IDs: FCCC-86814, NCI-V87-0282
16.	Phase III Comparison of Initial Endocrine Therapy (Orchiectomy or Leuprolide/Flutamide) Followed at Relapse by Chemotherapy (ADR/MITO/VBL) vs Initial Chemotherapy plus Endocrine Therapy in Patients with Unresectable or Metastatic Prostatic Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: over 20 to 80 Sponsor: Protocol IDs: MDA-DM-88027, NCI-V88-0440
17.	Phase III Randomized Trial of Casodex vs Flutamide in Combination with either Leuprolide or Goserelin in Patients with Previously Untreated Stage D2 Prostatic Cancer Phase: Phase III Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: MSKCC-92050, NCI-V92-0124
18.	Phase III Randomized Trial of Immediate vs Delayed Hormone Therapy in Patients with Newly Diagnosed, Locally Advanced or Asymptomatic Metastatic Prostate Cancer (Summary Last Modified 04/93) Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: MRC-PROST, EU-90038
19.	Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse Phase: Phase III Type: Treatment Status: Closed Age: Under 80 Sponsor: Other Protocol IDs: CDR0000270970, FRE-FNCLCC-GETUG-12/0203, EU-20238, NCT00055731
20.	Clinical Trial for Prostate Cancer Phase: Phase III Type: Treatment Status: Completed Age: 40 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OL-007, NCT00076531
21.	Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRO-04-62, NCT00128531
22.	Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0521, NCT00288080
23.	The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FE200486 CS21, NCT00295750
24.	Phase III Randomized Study of Zoledronate in Preventing Osteoporosis and Associated Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiotherapy and Luteinizing Hormone-Releasing Hormone Agonist Therapy Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0518, 0518, NCT00329797
25.	Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP6976J_3501, EudraCT # : 2004-002203-32, UCLA-0511090-01, SANOFI-XRP6976J/3501, NCT00283062